ROS1 and non-small cell lung carcinoma: Additionally, a subanalysis of the Crizotinib in the Pretreated Metastatic NSCL With MET Amplification or ROS1 Translocation (METROS) trial including 48 ROS1-rearranged patients and 26 MET-mutated NSCLC patients demonstrated that ROS1-rearranged patients had an increased incidence of VTE compared to MET-mutated patients (41.6% vs. 15.3%) [33].